Delivery Order SPE2DB22D1017-SPE2DB25FG7UD
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,745.89 to AmerisourceBergen Drug Corp for 180 tablets of Janumet XR 50-1,000 mg on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order was competitively awarded without set-aside provisions. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) valued at $3,328.77. This firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen's larger indefinite delivery contract with DLA. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,086.48 to supply Janumet XR 100-1,000 mg tablets (90-count) with an ultimate completion date of July 25, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a single delivery order under a larger contract vehicle. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $19,423.78. This firm fixed-price delivery order represents a non-set-aside, competitively awarded transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX. The ultimate completion date for this delivery order is August 5,...
- The Defense Logistics Agency awarded a delivery order valued at $4,193.47 to AmerisourceBergen Drug Corp for the supply of Janumet XR 50-1,000 mg tablets (180-count units). This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Janumet 50-1,000 mg tablets (180 count) with a contract ceiling value of $4,393.68. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion on July 23, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $3,032.22 firm fixed price delivery order to AmerisourceBergen Drug Corp for 180 tablets of Janumet XR 50-1,000 mg, with an ultimate completion date of July 29, 2025. This non-set-aside competitive award was issued on July 28, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,417.63 to AmerisourceBergen Drug Corp for 180 tablets of Janumet 50-1,000 mg on July 29, 2025, with completion scheduled for July 30, 2025. This competitively awarded delivery order, utilizing firm fixed pricing with no set-aside designation, represents pharmaceutical procurement under AmerisourceBergen's broader supply agreement with the federal government. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a $1,913.29 firm fixed price delivery order to AmerisourceBergen Drug Corp for 180 tablets of Janumet 50-1,000 mg on August 14, 2025, with completion scheduled for August 15, 2025. This non-set-aside competitive award represents a pharmaceutical delivery under the agency's medical supply procurement operations. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal healthcare systems and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Janumet XR 50-1,000 mg tablets (180-count units) with a ceiling value of $2,511.68. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. As a child contract under...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG7UDDelivery Order
The Defense Logistics Agency awarded a $9,327.27 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 180 tablets of Janumet XR 50-1,000 mg, with an ultimate completion date of July 22, 2025. This non-set-aside award was issued on July 21, 2025, and represents a pharmaceutical supply delivery to support federal medical procurement needs. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, maintains an extensive federal contract portfolio with DLA covering diabetes medications, neurological treatments, pain management pharmaceuticals, and other specialized medical commodities, demonstrating the company's significant role in supporting defense medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.3k | 7/21/25 |